Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
- de Joode, Karlijn
- Tol, Jolien
- Hamberg, Paul
- Cloos, Marissa
- Kastelijn, Elisabeth A.
- Borgers, Jessica S.W.
- Nuij, Veerle J.A.A.
- Klaver, Yarne
- Herder, Gerarda J.M.
- Mutsaers, Pim G.N.J.
- Dumoulin, Daphne W.
- Oomen-de Hoop, Esther
- van Diemen, Nico G.J.
- Libourel, Eduard J.
- Geraedts, Erica J.
- Bootsma, Gerben P.
- van der Leest, Cor H.
- Peerdeman, Anne L.
- Herbschleb, Karin H.
- Visser, Otto J.
- Bloemendal, Haiko J.
- van Laarhoven, Hanneke W.M.
- de Vries, Elisabeth G.E.
- Hendriks, Lizza E.L.
- Beerepoot, Laurens V.
- Westgeest, Hans M.
- van den Berkmortel, Franchette W.P.J.
- Haanen, John B.A.G.
- Dingemans, Anne Marie C.
- van der Veldt, Astrid A.M.
DOIAbstract
Aim of the study: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied in patients with cancer and COVID-19. Methods: The Dutch Oncology COVID-19 Consortium registry was launched in March 2020 in 45 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in patients with cancer. Here, an updated analysis of the registry was performed, and treatment restrictions (e.g. do-not-intubate codes) were studied in relation to COVID-19 outcomes in patients with cancer. Oncological tr...
Add to ORKG